EUROPLASMA (ALEUP.PA)

FR001400PDG8 - Common Stock

0.0335  0 (-6.94%)

Fundamental Rating

0

Overall ALEUP gets a fundamental rating of 0 out of 10. We evaluated ALEUP against 44 industry peers in the Commercial Services & Supplies industry. Both the profitability and financial health of ALEUP have multiple concerns. ALEUP is valued expensive and it does not seem to be growing.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALEUP had negative earnings in the past year.
ALEUP had a negative operating cash flow in the past year.
ALEUP had negative earnings in each of the past 5 years.
ALEUP had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of ALEUP (-14.70%) is worse than 92.50% of its industry peers.
The Return On Equity of ALEUP (-154.05%) is worse than 95.00% of its industry peers.
Industry RankSector Rank
ROA -14.7%
ROE -154.05%
ROIC N/A
ROA(3y)-31.01%
ROA(5y)-37.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ALEUP has a worse Gross Margin (10.61%) than 82.50% of its industry peers.
In the last couple of years the Gross Margin of ALEUP has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for ALEUP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 10.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y0.18%

More info and screens

0

2. Health

2.1 Basic Checks

ALEUP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALEUP has been increased compared to 1 year ago.
The number of shares outstanding for ALEUP has been increased compared to 5 years ago.
ALEUP has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -2.30, we must say that ALEUP is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.30, ALEUP is not doing good in the industry: 90.00% of the companies in the same industry are doing better.
ALEUP has a Debt/Equity ratio of 1.03. This is a high value indicating a heavy dependency on external financing.
ALEUP has a Debt to Equity ratio of 1.03. This is in the lower half of the industry: ALEUP underperforms 65.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF N/A
Altman-Z -2.3
ROIC/WACCN/A
WACC3.81%

2.3 Liquidity

ALEUP has a Current Ratio of 0.74. This is a bad value and indicates that ALEUP is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.74, ALEUP is not doing good in the industry: 90.00% of the companies in the same industry are doing better.
A Quick Ratio of 0.35 indicates that ALEUP may have some problems paying its short term obligations.
With a Quick ratio value of 0.35, ALEUP is not doing good in the industry: 97.50% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.74
Quick Ratio 0.35

More info and screens

2

3. Growth

3.1 Past

ALEUP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 97.42%, which is quite impressive.
ALEUP shows a strong growth in Revenue. In the last year, the Revenue has grown by 64.73%.
The Revenue has been growing slightly by 6.40% on average over the past years.
EPS 1Y (TTM)97.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)64.73%
Revenue growth 3Y59.52%
Revenue growth 5Y6.4%
Sales Q2Q%117.09%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALEUP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALEUP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EUROPLASMA

EPA:ALEUP (1/6/2025, 7:00:00 PM)

0.0335

0 (-6.94%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryCommercial Services & Supplies
Earnings (Last)10-25 2024-10-25
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap299.15K
Analysts86.67
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.01
P/FCF N/A
P/OCF N/A
P/B 0.05
P/tB 0.05
EV/EBITDA N/A
EPS(TTM)-462.4
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.02
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS2.67
BVpS0.73
TBVpS0.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.7%
ROE -154.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 10.61%
FCFM N/A
ROA(3y)-31.01%
ROA(5y)-37.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y0.18%
F-Score5
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.16%
Cap/Sales 6.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.74
Quick Ratio 0.35
Altman-Z -2.3
F-Score5
WACC3.81%
ROIC/WACCN/A
Cap/Depr(3y)90.95%
Cap/Depr(5y)106.41%
Cap/Sales(3y)28.87%
Cap/Sales(5y)45.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)64.73%
Revenue growth 3Y59.52%
Revenue growth 5Y6.4%
Sales Q2Q%117.09%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-29.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y62.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.59%
OCF growth 3YN/A
OCF growth 5YN/A